ArticleBMJ neurology open2025
Efficacy and safety of oral amantadine in Parkinson's disease with dyskinesia and motor fluctuations: a systematic review and meta-analysis of randomised controlled trials.
Article in BMJ neurology open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Parkinson's disease: pathogenesis and therapeutic strategies.Molecular biomedicine · 2026Review
- Current and emerging drugs for Parkinson's disease: mechanisms, clinical evidence, and future directions.Frontiers in pharmacology · 2026Review
- Efficacy and safety of oral amantadine in Parkinson's disease with dyskinesia and motor fluctuations: a systematic review and meta-analysis of randomised controlled trials.BMJ neurology open · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oral amantadine is available in three formulations with distinct pharmacokinetics: immediate-release (IR), delayed-release/extended-release (DR/ER) and immediate-release/extended-release (IR/ER). While all formulations alleviate levodopa-induced dyskinesia, only DR/ER has shown efficacy for motor fluctuations. This meta-analysis evaluates the impact of amantadine formulations on motor complications in Parkinson's disease (PD). Methods: A systematic search of PubMed and Scopus (inception to February 2024) identified randomised controlled trials (RCTs) evaluating dyskinesia using various Dyskinesia Rating Scales (DRS) and Unified Parkinson's Disease Rating Scale (UPDRS) or Movement Disorder Society (MDS)-UPDRS part 4 subscores ((MDS-)UPDRS IV), motor fluctuations using 'OFF' time and safety through adverse events. Subgroup analysis assessed formulation-specific effects. The I² statistic determined the use of fixed-effects or random-effects models for efficacy outcomes. Dyskinesia was analysed using standardised mean difference (SMD), motor fluctuations with mean difference (MD) and adverse events with ORs via a fixed-effects Mantel-Haenszel model. Results: Fourteen RCTs (13 articles) were included. Amantadine significantly reduced dyskinesia (DRS: SMD=-1.32, 95% CI (-1.78 to -0.86); (MDS-)UPDRS IV: SMD=-0.95, 95% CI (-1.33 to -0.58)), with similar effects across formulations. 'OFF' time decreased significantly (MD=-0.66, 95% CI (-0.93 to -0.40)), notably with IR (MD=-0.75, 95% CI (-1.41 to -0.10)) and DR/ER (MD=-0.96, 95% CI (-1.35 to -0.57)), but not IR/ER (MD=-0.23, 95% CI (-0.68 to 0.22)). Adverse events (OR=3.30, 95% CI (2.29 to 4.74)) included dry mouth, hallucinations, peripheral oedema, dizziness and constipation. Conclusions: All amantadine formulations alleviated dyskinesia. Additionally, DR/ER improved motor fluctuations, while IR demonstrated benefits, although the evidence is limited by short study durations. PROSPERO registration number: CRD42024513081.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.